Delivery Order SPE2DB22D3301-SPE2DB25FY9YN
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Barhemsys 10 mg/4 ml vials with a ceiling value of $12.7K. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competitively awarded. This delivery order is issued under...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,024.38 firm fixed-price delivery order is for the supply of the medication BARHEMSYS 5 MG/2 ML VIAL 2ML. The contract has an ultimate completion date of August 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,994.83 to AmerisourceBergen Drug Corp for BARHEMSYS 5 mg/2 mL vials on August 18, 2025, with completion targeted for August 19, 2025. This firm fixed-price delivery order, which was not set-aside for small business or other designated groups, represents a competitively awarded transaction supporting federal medical procurement needs. The contractor's corporate office, located in Conshohocken, Pennsylvania, served as the...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,386.01 firm fixed-price delivery order is for the supply of BARHEMSYS 10 MG/4 ML VIAL 4ML, a pharmaceutical product. The contract has an ultimate completion date of August 1, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $10,264.66, is for the supply of BARHEMSYS 10 MG/4 ML VIAL 4ML, a pharmaceutical product. The contract is a delivery order with a firm fixed price and an ultimate completion date of December 30, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
- This federal contract award, valued at $5,665.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BARHEMSYS 10 MG/4 ML VIAL 4ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This federal contract award, valued at $5,574.15, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BARHEMSYS 10 MG/4 ML VIAL 4ML, a pharmaceutical product, with a completion date of October 10, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type, and it was not set aside for any specific business size or socioeconomic category....
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of BARHEMSYS 5 MG/2 ML VIAL 2ML, a pharmaceutical product, with a ceiling value of $1,872.03 and a period of performance through June 25, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen Drug Corporation holds a...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,215.41, is for the delivery of BARHEMSYS 5 MG/2 ML VIAL 2ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $43,377.81 to AmerisourceBergen Drug Corp on August 18, 2025, with completion expected by August 19, 2025. This firm fixed-price, competitively awarded delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion and extends through December 2026. The delivery order represents a child contract...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY9YNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,439.09 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Barhemsys 10 mg/4 ml vials. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 26, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a wide range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to military and veteran healthcare systems. The company's contract awards with the Defense Logistics Agency demonstrate its capability to fulfill federal pharmaceutical requirements through open competition, with delivery orders consistently structured as firm fixed-price arrangements. This award reflects the company's ongoing role in supporting the military medical supply chain across multiple therapeutic domains and customer bases including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 8/25/25 |